BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG
411 results:

  • 1. Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.
    McCarthy G; Young K; Madin-Warburton M; Mantaian T; Brook E; Metcalfe K; Mikelson J; Xu R; Seyla-Hammer C; Aguiar-Ibáñez R; Amonkar M
    J Med Econ; 2024; 27(1):279-291. PubMed ID: 38293714
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [A Case of Stage Ⅳc dMMR Transverse Colon cancer with Complete Response to Combination Therapy with Immune Checkpoint Inhibitor in Stage ⅣB Lung Adenocarcinoma].
    Kageyama C; Yoshimatsu K; Tanaka H; Higashida M; Ito Y; Okada T; Endo S; Fujiwara Y; Ueno T
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1114-1116. PubMed ID: 38035848
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Impacts of some clinicopathodemography and colorectal tissues key cell cycle and mucin stabilizing molecules on the metastasis trend in colorectal cancer patients.
    Ghorbani Ranjbary A; Mehrzad J; Rahbar N; Dehghani H
    Mol Biol Rep; 2023 Oct; 50(10):8589-8601. PubMed ID: 37644368
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic colorectal cancer on pembrolizumab: A Case Report.
    Krekeler C; Wethmar K; Mikesch JH; Kerkhoff A; Menck K; Lenz G; Schildhaus HU; Wessolly M; Hoffmann MW; Pascher A; Asmus I; Wardelmann E; Bleckmann A
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569431
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in colorectal cancer and Invasive Breast cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Electrochemical biotool for the dual determination of epithelial mucins associated to prognosis and minimal residual disease in colorectal cancer.
    Tejerina-Miranda S; Blázquez-García M; Serafín V; Montero-Calle A; Garranzo-Asensio M; Reviejo AJ; Pedrero M; Pingarrón JM; Barderas R; Campuzano S
    Int J Biol Macromol; 2023 Sep; 248():125996. PubMed ID: 37499706
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. GART Functions as a Novel Methyltransferase in the RUVBL1/β-Catenin Signaling Pathway to Promote Tumor Stemness in colorectal cancer.
    Tang C; Ke M; Yu X; Sun S; Luo X; Liu X; Zhou Y; Wang Z; Cui X; Gu C; Yang Y
    Adv Sci (Weinh); 2023 Sep; 10(25):e2301264. PubMed ID: 37439412
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Dissecting the genetic heterogeneity of gastric cancer.
    Hess T; Maj C; Gehlen J; Borisov O; Haas SL; Gockel I; Vieth M; Piessen G; Alakus H; Vashist Y; Pereira C; Knapp M; Schüller V; Quaas A; Grabsch HI; Trautmann J; Malecka-Wojciesko E; Mokrowiecka A; Speller J; Mayr A; Schröder J; Hillmer AM; Heider D; Lordick F; Pérez-Aísa Á; Campo R; Espinel J; Geijo F; Thomson C; Bujanda L; Sopeña F; Lanas Á; Pellisé M; Pauligk C; Goetze TO; Zelck C; Reingruber J; Hassanin E; Elbe P; Alsabeah S; Lindblad M; Nilsson M; Kreuser N; Thieme R; Tavano F; Pastorino R; Arzani D; Persiani R; Jung JO; Nienhüser H; Ott K; Schumann RR; Kumpf O; Burock S; Arndt V; Jakubowska A; Ławniczak M; Moreno V; Martín V; Kogevinas M; Pollán M; Dąbrowska J; Salas A; Cussenot O; Boland-Auge A; Daian D; Deleuze JF; Salvi E; Teder-Laving M; Tomasello G; Ratti M; Senti C; De Re V; Steffan A; Hölscher AH; Messerle K; Bruns CJ; Sīviņš A; Bogdanova I; Skieceviciene J; Arstikyte J; Moehler M; Lang H; Grimminger PP; Kruschewski M; Vassos N; Schildberg C; Lingohr P; Ridwelski K; Lippert H; Fricker N; Krawitz P; Hoffmann P; Nöthen MM; Veits L; Izbicki JR; Mostowska A; Martinón-Torres F; Cusi D; Adolfsson R; Cancel-Tassin G; Höblinger A; Rodermann E; Ludwig M; Keller G; Metspalu A; Brenner H; Heller J; Neef M; Schepke M; Dumoulin FL; Hamann L; Cannizzaro R; Ghidini M; Plaßmann D; Geppert M; Malfertheiner P; Gehlen O; Skoczylas T; Majewski M; Lubiński J; Palmieri O; Boccia S; Latiano A; Aragones N; Schmidt T; Dinis-Ribeiro M; Medeiros R; Al-Batran SE; Leja M; Kupcinskas J; García-González MA; Venerito M; Schumacher J
    EBioMedicine; 2023 Jun; 92():104616. PubMed ID: 37209533
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A systematic review of clinical trials of treatment regimens in HER2-amplified metastatic colorectal cancer.
    Sur D; Lungulescu C; Dumitrescu EA; Afrăsânie V; Spînu Ș; Lungulescu CV; Schmoll HJ
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):633-641. PubMed ID: 37127555
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Clinicopathological Factors Affecting Mucin 1, Mucin 2, and Mucin 5AC Staining in Patients who Underwent Resection for colorectal cancer.
    Anuk T; Beseren H; Polat Y; Ozden O; Kalayci T
    J Coll Physicians Surg Pak; 2023 Mar; 33(3):335-340. PubMed ID: 36945166
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Immunophenotypic profiles and prognosis for colorectal mucinous adenocarcinomas are dependent on anatomic location.
    Patel C; Behring M; Al Diffalha S; Dhall D; Lee G; Shanmugam C; Grizzle WE; Manne U
    Cancer Med; 2023 Apr; 12(8):9637-9643. PubMed ID: 36916704
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Randomized, Double-Blind, Placebo-Controlled Trial of muc1 Peptide Vaccine for Prevention of Recurrent colorectal Adenoma.
    Schoen RE; Boardman LA; Cruz-Correa M; Bansal A; Kastenberg D; Hur C; Dzubinski L; Kaufman SF; Rodriguez LM; Richmond E; Umar A; Szabo E; Salazar A; McKolanis J; Beatty P; Pai RK; Singhi AD; Jacqueline CM; Bao R; Diergaarde B; McMurray RP; Strand C; Foster NR; Zahrieh DM; Limburg PJ; Finn OJ
    Clin Cancer Res; 2023 May; 29(9):1678-1688. PubMed ID: 36892581
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. muc1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
    Krimmel L; Quante M; Bengsch B
    Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genetic alterations shaping tumor response to anti-EGFR therapies.
    Vaquero J; Pavy A; Gonzalez-Sanchez E; Meredith M; Arbelaiz A; Fouassier L
    Drug Resist Updat; 2022 Sep; 64():100863. PubMed ID: 36063655
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
    Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 1.
    Kalke K; Orpana J; Lasanen T; Esparta O; Lund LM; Frejborg F; Vuorinen T; Paavilainen H; Hukkanen V
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746761
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-muc1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
    Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
    ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 21.